AtriCure Inc (AtriCure) is a medical device company that focuses on surgical therapies for atrial fibrillation (AF), left atrial appendage (LAA) management to help reduce stroke risk, and cryoablation-based post-operative pain management. Its products are used in surgeries such as valve repair/replacement or coronary artery bypass and minimally invasive or hybrid approaches that combine surgical epicardial ablation with catheter ablation by electrophysiologists. AtriCure’s cardiac ablation portfolio includes radiofrequency (RF) platforms such as the Isolator Synergy clamps and the EnCompass clamp designed to improve the efficiency of lesion creation, multifunction RF pens and linear ablation devices used to complete lesion sets; it also offers the cryoICE cryoablation system for surgical cryoablation. The company provides the EPi-Sense and EPi-Sense ST systems for Hybrid AF Therapy in long-standing persistent AF when used with endocardial catheter ablation. The company’s AtriClip left atrial appendage (LAA) management product line provides the AtriClip LAA Exclusion System including FLEX-Mini and PRO-Mini. The company’s pain management product line provides cryoSPHERE probes, cryoSPHERE+, cryoSPHERE MAX variants and the cryoXT. The company categorizes its revenue across various product segments, including open ablation, minimally invasive ablation, pain management, and appendage management. AtriCure sells products directly to medical centers in the US, Germany, France, the UK, the Benelux region, Australia, and Canada. The company has established a wholly owned subsidiary, AtriCure Europe BV, in the Netherlands to facilitate distribution in European and Middle Eastern markets. AtriCure maintains a network of distributors across Asia, Europe, South America, and Canada. Revenue is geographically segmented into four regions: the US, Europe, Asia-Pacific, and Other International. The company markets its products in approximately 50 countries and has sold over 750,000 AtriClip devices worldwide.

AtriCure is actively engaged in R&D activities to expand treatment options and increase awareness in current markets, also enabling expansion into adjacent markets. The company is involved in developing and researching new and existing products or concepts, conducting preclinical studies, clinical trials, and other regulatory activities. Significant investments are made in product development and clinical science activities to drive the advancement and adoption of new therapies. Key clinical trials include BoxX-NoAF, LeAAPS, HEAL-IST, CONVERGE, ICE-AFIB, and CEASE-AF, which focus on validating the long-term results of procedures using AtriCure's products and supporting applications to regulatory agencies for expanded indications. The R&D unit of AtriCure is responsible for supporting the company's business strategy by expanding treatment options and increasing awareness in current markets, also enabling expansion into adjacent markets. The unit is engaged in developing and researching new and existing products or concepts, conducting preclinical studies, clinical trials, and other regulatory activities. AtriCure holds numerous issued United States and international patents and has multiple pending United States and international patent applications. In FY2025, the company spent US$99.2 million on its R&D activities, which as a percentage of revenue stood at 18.5% and grew 3.2% YoY.